Ads
related to: cabozantinib renal cell carcinoma- Co-Pay Program
Find Information On Financial
Support For CABOMETYX®.
- Taking Your CABOMETYX®
Learn More About How To Take
CABOMETYX® & View Dosing Info.
- Patient Videos
Visit To Watch Videos To
Learn More About CABOMETYX®.
- Patient Handbook
Get CABOMETYX® Information By
Downloading A Patient Handbook.
- BE CONNECTED Program
Sign Up To Find Information
On A CABOMETYX® Support Program.
- Exelixis Access Services®
Learn More About Cost &
Financial Support.
- Co-Pay Program
Search results
Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
GuruFocus.com via Yahoo Finance· 2 months agoExelixis Inc. (NASDAQ:EXEL) is a pharmaceutical company headquartered in Alameda, California that...
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
Zacks via Yahoo Finance· 1 year agoShares of Exelixis, Inc. EXEL were down 0.17% on Mar 3 after the company announced the failure of...
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
Zacks via Yahoo Finance· 1 year agoThe biotech sector was in focus with key pipeline and regulatory updates. Among these, BMRN was down...
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Benzinga via Yahoo Finance· 1 year agoExelixis Inc (NASDAQ: EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary...
Is Exelixis' (EXEL) Growth Story Likely to Continue?
Zacks via Yahoo Finance· 2 years agoExelixis EXEL, an oncology-focused company, maintains momentum on the back of the solid performance of its lead drug Cabometyx amid stiff competition...
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
Zacks via Yahoo Finance· 8 months agoExelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
Zacks via Yahoo Finance· 3 months agoExelixis, Inc. EXEL reported earnings of 33 cents per share in the fourth quarter of 2023, which...
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
Benzinga via Yahoo Finance· 2 years agoExelixis Inc (NASDAQ: EXEL) announced detailed results from the COSMIC-313 Phase 3 trial...
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
Zacks via Yahoo Finance· 3 months agoExelixis, Inc. EXEL announced that it has successfully defended an EU patent for Cabometyx...
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced detailed results from the ongoing phase III study, COSMIC-313. The...
Ads
related to: cabozantinib renal cell carcinoma